Recently sorafenib, another kinase inhibitor already licensed for treatment of some cancers (Gadaleta-Caldarola et al., 2015), was reported to activate AMPK in tumor cell lines (Fumarola et al., 2013, Groenendijk et al., 2015). This evidence concerns the gene PRKAA2 and cancer.